RTI Surgical (NASDAQ:RTIX) Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of RTI Surgical (NASDAQ:RTIX) from a hold rating to a sell rating in a research report sent to investors on Saturday morning, Zacks.com reports.

According to Zacks, “RTI Surgical Inc. is a surgical implant company. Its implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures. RTI Surgical Inc., formerly known as RTI Biologics, Inc., is headquartered in Alachua, Fla. “

Separately, Cantor Fitzgerald began coverage on shares of RTI Surgical in a report on Wednesday, May 29th. They set an overweight rating and a $7.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $6.50.

Shares of RTIX opened at $3.18 on Friday. RTI Surgical has a 12 month low of $2.95 and a 12 month high of $6.15. The firm’s 50 day moving average is $3.90 and its 200-day moving average is $4.68. The stock has a market capitalization of $228.35 million, a PE ratio of 26.50 and a beta of 1.37. The company has a current ratio of 3.14, a quick ratio of 1.22 and a debt-to-equity ratio of 0.27.

RTI Surgical (NASDAQ:RTIX) last announced its earnings results on Thursday, August 1st. The medical equipment provider reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. RTI Surgical had a negative net margin of 1.08% and a positive return on equity of 3.55%. The company had revenue of $82.31 million for the quarter. Equities research analysts predict that RTI Surgical will post 0.02 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. increased its stake in RTI Surgical by 214.7% in the first quarter. Meeder Asset Management Inc. now owns 5,878 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 4,010 shares during the last quarter. Jane Street Group LLC bought a new position in RTI Surgical in the second quarter valued at approximately $65,000. BNP Paribas Arbitrage SA increased its stake in RTI Surgical by 686.8% in the first quarter. BNP Paribas Arbitrage SA now owns 11,771 shares of the medical equipment provider’s stock valued at $71,000 after acquiring an additional 10,275 shares during the last quarter. Marshall Wace North America L.P. bought a new position in RTI Surgical in the first quarter valued at approximately $79,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in RTI Surgical in the fourth quarter valued at approximately $81,000. 58.08% of the stock is currently owned by institutional investors and hedge funds.

RTI Surgical Company Profile

RTI Surgical Holdings, Inc, a surgical implant company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.

Read More: Intrinsic Value and Stock Selection

Get a free copy of the Zacks research report on RTI Surgical (RTIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.